Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).
- DOI
- 10.1177/17588359251340554
- Published
- 2025
- Container
- Therapeutic advances in medical oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17588359251340554,
title = {Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).},
author = {Shadman M and Brown JR and Williams R and Mohseninejad L and Yang K and Rakonczai P and Lamanna N and Xu S and Cleary Cohen A and O'Brien SM and Tedeschi A and Tam CS},
year = {2025},
journal = {Therapeutic advances in medical oncology},
doi = {10.1177/17588359251340554},
url = {https://doi.org/10.1177/17588359251340554}
}RIS
TY - JOUR TI - Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC). AU - Shadman M AU - Brown JR AU - Williams R AU - Mohseninejad L AU - Yang K AU - Rakonczai P AU - Lamanna N AU - Xu S AU - Cleary Cohen A AU - O'Brien SM AU - Tedeschi A AU - Tam CS PY - 2025 JO - Therapeutic advances in medical oncology DO - 10.1177/17588359251340554 UR - https://doi.org/10.1177/17588359251340554 ER -
APA
M, S., JR, B., R, W., L, M., K, Y., P, R., N, L., S, X., A, C. C., SM, O., A, T., & CS, T. (2025). Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC).. Therapeutic advances in medical oncology. https://doi.org/10.1177/17588359251340554
Source records
- pubmed · retrieved 2026-11-10T16:48:14.491Z